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1. Introduction 
A protein inhibitor specific for thiol proteinases is 
present in human serum [1 ]. Two forms of this inhib- 
itor have been purified [2,3] and named a-TPI. A 
thiol proteinase inhibitor has been demonstrated in 
human urine and this has been shown to be a degrada- 
tion product of the plasma inhibitors [4]. The plasma 
protein strongly inhibits papain and ficin but inhibits 
cathepsin B, a typical ysosomal thiol proteinase, only 
weakly [1,3]. Here, we describe the inhibition of 
cathepsin L, another lysosomal thiol proteinase [5], 
by this plasma inhibitor. The results obtained suggest 
that one of the physiological functions of a-TPI is to 
inhibit cathepsin L. 
activity was assayed with the Boehringer UV system 
(Mannheim). 
The activity of papain was measured using BANA 
as substrate. For cathepsin L, the activity was tested 
using BANA, azocasein, aldolase, Arg-N-Nap and 
Leu-N-Nap as substrates. Azocasein was prepared by 
treating a-casein with diazotized sodium sulphanilate 
according to [6]. The inhibition of papain by a-TPI 
was assayed using BANA as substrate and for cathep- 
sin L the inhibition by a-TPI was carried out with 
azocasein as substrate. The experimental conditions 
and the procedure for the activity measurements and 
the inhibition tests are described in [7]. Acrylamide- 
gel electrofocusing was performed according to [8] 
and SDS acrylamide-gel electrophoresis according to 
[9]. 
2. Materials and methods 
Ascites fluid or pleural fluid was used for the prep- 
aration of a-TPI. Human livers free from disease were 
used for the preparation ofcathepsin L. These starting 
materials were stored at -20°C until required. Papain, 
ficin, a-casein, BANA, Arg-N-Nap, Leu-N-Nap, ammo- 
nium sulphamate, sodium nitrite, N-(1-naphthyl)- 
ethylenediamine,/3-naphthylamine were purchased 
from Sigma (St Louis MO). 
CNBr-activated Sepharose 4B and Sephadex G-75 
(superfine) were supplied by Pharmacia Fine Chemi- 
cals (Uppsala). CM-ceUulose (CM 32) and Ultrogel 
ACA 44 were purchased from Whatman (Maidstone 
Kent) and IBF (Gennevilliers), respectively. Aldolase 
Abbreviations: TPI, a-thiol proteinase inhibitor; CL, cathep- 
sin L (EC 3.3.22.15); BANA,N-benzoyl-D,L-axginine-2-naph- 
thylamide -hydrochloride; Arg-N-Nap, L-arginine-2-naphthyl- 
amide-hydrochloride; Leu-N-Nap, L-leucine-2-naphthylam- 
ide -hydrochloride 
2.1. Preparation o f  a-TPI 
a-TPI was purified as in [2]. The starting material 
was submitted to acid precipitation and, after centrif- 
ugation, the supernatant was neutralized. This was 
followed by affinity chromatography of the superna- 
tant on a column of ficin-Sepharose (2cm X 5 cm): 
20 ml acid-treated fluid were used for each affinity 
chromatography. The 2 forms of a-TPI were fraction- 
ated on a column of Ultrogel ACA 44 (3 cm X 70 cm). 
During the different stages of the purification a-TPI 
was assayed for its inhibition capacity against papain. 
The concentration f the purified inhibitor was cal- 
culated from the absorbance at280 nm by using 
E~ m -- 5.9 [3] and anM r of 90 000 (a-TPI (1)) or 
175 000 (a-TPI (2)) [2,3,10]. 
2.2. Preparation o f  human liver cathepsin L
The enzyme was purified by the method escribed 
for rat liver cathepsin B. 
After homogenization f a piece of human liver 
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(200-250 g) with Triton X-100 (0.2%, v/v) and acid 
precipitation atpH 3.8, the soluble material was 
extracted by stirring overnight at 4°C. The insoluble 
fraction was removed by centrifugation at 16 300 X g 
for 30 min. This was followed by precipitation with 
ammonium sulphate (2-3 M). After dialysis and cen- 
trifugation, the brown supernatant was applied to a 
CM 32 column equilibrated with 0.1 M sodium ace- 
tate buffer (pH 5.30). Cathepsin B emerged in the 
breakthrough peak. Cathepsin L, absorbed on the ion- 
exchange resin, was eluted with 0.15 M phosphate 
buffer (pH 7.50) according to [11 ]. Cathepsin L was 
isolated by a single gel filtration on Sephadex G-75 
(superfine). For cathepsin B two gel filtrations under 
the same conditions were required. The protein con- 
centration of purified cathepsin L was determined as 
in [12] with bovine serum albumin as standard. The 
absorption coefficient E18% 0 nm, 1 cm was calculated 
on this basis. The M r of the enzyme was measured by 
polyacrylamide g ls electrophoresis in the presence of 
1% (w/v) SDS and 2% dithiotreitol. 
activity of cathepsin H [13,14]. On this basis, it may 
be taken that our purified cathepsin L is free from 
cathepsin B and cathepsin H activities. Aldolase inac- 
tivation has been reported as a specific property of 
pl 
4- .85 
3. Results 
3.1. Analysis of a-TPI and CL 
The purified inhibitor was studied by gel electro- 
focusing, a-TPI (1) exhibited aband at pI 4.85 when 
the pH gradient was made with ampholines ranging I~ l  
between pH 3.50-10. When the experiment was done 
II-y 
at pH 4.0-6.5 two bands at pI 4.80 and 4.95 were 
seen (fig. 1): the heterogeneity of a-TPI (1)has been 
reported by different authors [2,3,10]. a-TPI (2) 
showed one band at the bottom of the gel and a pI of 
3.60 could be measured. Our results agree with [2] 
on the different molecular forms of a-TPI. 
Purified cathepsin L was submitted to acrylamide 
gel electrofocusing. Over a gradient of pH 3.5-10 this 
enzyme xhibited 2 bands at pI 5.50 and 5.70 (fig.l). 
An M r of 30 000 was found on SDS-polyacrylamide 
gels (fig.2). There is no report on the properties of 
human hver CL though the properties of the rat liver 3,80 ~_ 
enzyme have been described [5]. The human enzyme 
had similar catalytic properties to those of the rat 
enzyme (table 1): a high proteolytic activity azocasein 
and a very low activity with BANA as substrate (a 
good substrate for the endopeptidase activity of 
cathepsin B and cathepsin H). Our preparation had no 
activity with Arg-N-Nap and Leu-N-Nap as substrates, 
used for the measurement of the aminopeptidase 
a b 
pl 
c d 
Fig. 1. Gel electrofocusing of the proteins tudied: (a) aTPI 
(1) (25 #g sample) pH 3.5-10.0; (b) aTPI (1) (25 #g sample) 
pH 4.0-6.5; (c) aTPI (2) (25 #g sample) pH 3.5-10.0; (d) 
cathepsin L (25/~g sample) pH 3.5-10.0. 
308 
Volume 138, number 2 FEBS LETTERS February 1982 
cathepsin B [15] and is an example of peptidyl-dipep- 
tidase activity. This property has also been found for 
human liver cathepsin L (table 1), studies with the rat 
liver enzyme having been reported in [16]. 
3.2. Inhibition study 
C,thepsin L activity using azocasein as substrate is
strongly inhibited by a-TPI (1) and t~-TPI (2) (fig.3). 
Fig.2. SDS-polyacrylamide g l electrophoresis forcathep- 
sin L (acrylamide 15%, SDS 1%) the sample were run after 
reduction by dithiotreitol (2%). The arrows at the bottom of 
the gels show the position of the tracking dye. (a) Mixture of 
standard proteins: phosphorylase b (M r 94 000); bovine 
serum albumin (M r 66 000); ovalbumin (M r 45 000); car- 
bonic anhydrase (M r 30 000); soya bean trypsin inhibitor 
(M r 20 100); a-lactalbumin (Mr 14 400). (b) Purified cathep- 
sin L (50 gg sample). 
Table 1 
Some properties of purified human liver cathepsin L 
Specific activities 
(mU/mg at pH 6.0) against: 
BANA 20 
Arg-N-Nap 0 
Leu-N-Nap 0 
Azocasein 150 
Aldolase 0.45 
E1% 11.40 280 nm,l cm 
Mr 30 000 
[sozymes 
Number 2 
pl 5.70 
5.50 
a Io0- 
> 
~m SO. 
o . . . .  0.5l ' 1J " i 
Mo lar  ra t io  ~TP|2/C L 
100 
so 
o 
0.S 
Molar ratio ~TPIt~CL 
Fig.3. Inhibition curves of cathepsin L by aTPI: (a) ,~TPI (1); 
(b) aTPI (2). The enzyme (0.33 nmol) was preincubated for 
10 rain at room temperature with aTPI (1) (0.02-0.78 nmol) 
or aI"PI (2) (0.01-0.83 nmol) in 400 ~1 final vol. The sub- 
strate (100 #1 azocaseine 1%, w]v) was then added and sam- 
ples were incubated for 2 h at 40°C. Initial cathepsin L activ- 
ity was determined inthe absence of other proteins. 
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The loss in enzyme activity is 80% with the 2 inhibi- 
tors and the inhibition curves how a plateau corre- 
lating with 1 binding site on the enzyme. 
4. Discussion 
from the Institut National de la Sant6 et de la 
Recherche M6dicale and from the UER Broussais- 
H6tel.Dieu, Universit6 Pierre et Marie Curie. The skill- 
ful technical assistance of Mrs V. Fumeron is acknowl- 
edged. 
Here we describe the purification of human liver 
cathepsin L and its inhibition by a-TPI (1) and a-TPI 
(2). Preceding reports on these plasma proteins [1-4] 
suggest that the inhibitors are group-specific to thiol 
proteinases, but only plant thiol proteinases are 
strongly inhibited. The poor inhibition of cathepsin B
[2] makes it difficult to understand the physiological 
function of these inhibitors. Our results how that 
one of the physiological roles of these plasma proteins 
is to inhibit cathepsin L. This enzyme has a high 
proteolytic activity and a very weak activity against 
synthetic substrate: this fact readily distinguishes 
cathepsin Lfrom the other 2 thiol proteinases (cathep- 
sin B and cathepsin H) and shows that cathepsin L 
can play an important role in tissue proteolysis n 
injury and inflammatory states. The strong inhibition 
of this enzyme by et-TPI suggests that this protein 
controls the tissue damage provoked by cathepsin L. 
However, it is known that a-TPI accumulates in 
extracellular fluid, e.g., the pleural cavity and ascites 
fluid, since here, the protein has been isolated from 
these fluids. This is in good agreement with the sug- 
gested physiological role of these inhibitors. 
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